TITLE

Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV

AUTHOR(S)
Akhavan, S.; Schnuriger, A.; Lebray, P.; Benhamou, Y.; Poynard, T.; Thibault, V.
PUB. DATE
August 2009
SOURCE
Journal of Infectious Diseases;8/15/2009, Vol. 200 Issue 4, p524
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To analyze the genetic diversity of the NS3 gene in patients infected with hepatitis C virus (HCV) genotype 4 (HCV-4) and to assess the possible effects of the gene polymorphism (or variability) on drug susceptibility, 43 NS3 gene sequences were determined for 53 selected patients with HCV-4 infection. NS3 sequencing, like NS5B sequencing, allowed correct subtype determination. Most residues that were located within the catalytic triad or the NS4-binding region or that were involved in metal binding were highly conserved and identical to those found in HCV genotype 1. Compared with HCV genotype 1, all HCV-4 NS3 protein presented V36L and C16T residue changes that could potentially reduce antiprotease activity. The efficacy of antiprotease in HCV-4-infected patients remains to be proven in large clinical trials.
ACCESSION #
43777871

 

Related Articles

  • Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. Tamaki, Nobuharu; Kurosaki, Masayuki; Higuchi, Mayu; Takada, Hitomi; Nakakuki, Natsuko; Yasui, Yutaka; Suzuki, Shoko; Tsuchiya, Kaoru; Nakanishi, Hiroyuki; Itakura, Jun; Takahashi, Yuka; Ogawa, Shintaro; Tanaka, Yasuhito; Asahina, Yasuhiro; Izumi, Namiki // PLoS ONE;9/9/2015, Vol. 10 Issue 9, p1 

    The assessment of individual risk of fibrosis progression in patients with chronic hepatitis C is an unmet clinical need. Recent genome-wide association studies have highlighted several genetic alterations as predictive risk factors of rapid fibrosis progression in chronic hepatitis C. However,...

  • Vitamin D and IL28B Genotyping as Predictors for Antiviral Therapy: A Retrospective Study in Egyptian HCV Genotype 4a. Abdelkader, Nadia Abdelaaty; Abdelmoniem, Soha Saoud; Sabry, Dina; Abdelbaky, Amin Mohamad; Mahdy, Maram M.; Zaky, Eman; Saad, Wessam Elsayed // Tropical Journal of Pharmaceutical Research;Oct2014, Vol. 13 Issue 10, p1725 

    Purpose: To evaluate the role of pre-treatment vitamin D serum level and interleukin28B (IL28B) (rs 12979860) polymorphism in chronic hepatitis C (CHC) genotype 4a patients treated with pegylated interferon a2-A and ribavirin (peg IFN+RBV) as predictors of response. Methods: A retrospective...

  • Do new HCV antivirals provide good value for money?  // PharmacoEconomics & Outcomes News;Jun2015, Vol. 730 Issue 1, p12 

    The article discusses various studies on the cost and cost effectiveness of hepatitis C virus (HCV) antivirals which were presented at the 2015 meeting of the International Society for Pharmacoeconomics and Outcomes Research. Topics covered include the analysis of HCV antiviral expenditures by...

  • Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. Echevarria, Desarae; Gutfraind, Alexander; Boodram, Basmattee; Major, Marian; Del Valle, Sara; Cotler, Scott J; Dahari, Harel // PLoS ONE;8/21/2015, Vol. 10 Issue 8, p1 

    Background/Aim: New direct-acting antivirals (DAAs) provide an opportunity to combat hepatitis C virus (HCV) infection in persons who inject drugs (PWID). Here we use a mathematical model to predict the impact of a DAA-treatment scale-up on HCV prevalence among PWID and the estimated cost in...

  • Measuring the Response of Extrahepatic Symptoms and Quality of Life to Antiviral Treatment in Patients with Hepatitis C. Isaacs, David; Abdelaziz, Nader; Keller, Majella; Tibble, Jeremy; Haq, Inam // Hepatitis Research & Treatment;2013, p1 

    Background. HCV infection is associated with musculoskeletal manifestations such as chronic widespread pain, sicca syndrome, polyarthritis, and a reduced HRQOL. Little data is available on the effect of treatment on these manifestations. This study measured changes in extrahepatic symptoms and...

  • Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Collins, Jeffrey M.; Raphael, Kara Loren; Terry, Charles; Cartwright, Emily J.; Pillai, Anjana; Anania, Frank A.; Farley, Monica M. // Clinical Infectious Diseases;10/15/2015, Vol. 61 Issue 8, p1304 

    Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis B virus (HBV)may increase the risk for HBV reactivation in coinfected patients. We present 2 cases of HBV reactivation during treatment with an all-oral regimen of...

  • Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Badri, Prajakta; King, Jennifer; Polepally, Akshanth; McGovern, Barbara; Dutta, Sandeep; Menon, Rajeev; Badri, Prajakta S; King, Jennifer R; Polepally, Akshanth R; McGovern, Barbara H; Menon, Rajeev M // Clinical Pharmacokinetics;Mar2016, Vol. 55 Issue 3, p275 

    The development of direct-acting antiviral (DAA) agents has reinvigorated the treatment of hepatitis C virus infection. The availability of multiple DAA agents and drug combinations has enabled the transition to interferon-free therapy that is applicable to a broad range of patients. However,...

  • Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome. Yoo, Eric R.; Perumpail, Ryan B.; Cholankeril, George; Ahmed, Aijaz // Case Reports in Infectious Diseases;10/26/2016, p1 

    Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past,...

  • NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. Zhou, Nannan; Hernandez, Dennis; Ueland, Joseph; Yang, Xiaoyan; Yu, Fei; Sims, Karen; Yin, Philip D.; McPhee, Fiona // Journal of Infectious Diseases;1/15/2016, Vol. 213 Issue 2, p206 

    Background: Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1-4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4-infected population for HCV genotype 4 subtype prevalence,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics